Quaker Chemical SEC Filings

Quaker Chemical Corporation senior vice president and Regional Commercial Lead-EMEA Miguel Moreno Hernandez reported routine equity award activity involving company common stock on December 15, 2025. He acquired 278 shares of common stock upon the vesting and settlement of restricted stock units and an additional 10 shares from dividend equivalent rights, both reported as option exercises or conversions (transaction code M).

To satisfy tax withholding obligations, 143 shares of common stock were disposed of at a price of $138.96 per share (transaction code F). After these transactions, he directly holds 1,942 shares of Quaker Chemical common stock. The filing explains that restricted stock units convert into common stock on a one-for-one basis and that the RSUs stemmed from a grant of 555 time-based units awarded on December 15, 2022, which vested 50% on June 15, 2024 and 50% on December 15, 2025.

Quaker Chemical Corp officer Andre Frodl, VP, R&D-Metals & Metalworking, reported equity transactions dated 12/15/2025 involving restricted stock units that converted into common stock. He acquired 172 shares of common stock upon vesting of restricted stock units and 6 shares from related dividend equivalent rights, each right being the economic equivalent of one share of KWR common stock.

On the same date, he disposed of 85 shares of common stock at $138.96 per share, and following these transactions he directly beneficially owned 611 shares of Quaker Chemical common stock. The underlying time-based restricted stock units were granted on 12/15/2022, vesting 50% on 06/15/2024 and 50% on 12/15/2025.

Quaker Chemical Corp. director reports complex equity transactions. A Form 4 filing for Quaker Chemical Corp. (KWR) discloses that a director entered into equity-linked transactions on 11/25/2025. The director disposed of 45,000 shares of common stock in one transaction and 30,000 shares in a second transaction, both coded J/K, and continued to hold 3,635,112 shares directly afterward.

The filing also reports four variable prepaid forward sale contracts referencing Quaker Chemical common stock. These derivative positions each relate to 192,200, 128,133, 13,900, and 9,267 underlying shares, respectively, and are shown as directly owned derivative securities. Additional details and mechanics of these contracts are described in Exhibit 99.1, which contains the explanation of responses.

Quaker Chemical Corp (KWR) disclosed insider transactions by a reporting person serving as a director and 10% owner. The form shows that on 11/25/2025, the reporting person, through QH Hungary Holdings Limited, disposed of 45,000 shares of common stock in one transaction and 30,000 shares in another. After these sales, the reporting person indirectly beneficially owned 3,665,112 and then 3,635,112 shares of common stock through QH Hungary Holdings Limited.

The reporting person also entered into several variable prepaid forward sale contracts referencing Quaker Chemical common stock on the same date. These derivative positions cover 192,200, 128,133, 13,900, and 9,267 shares of common stock, respectively, all held indirectly through QH Hungary Holdings Limited. Further details and key terms are referenced in Exhibit 99.1, which provides the notes and explanations for the coded transactions.

Quaker Chemical Corporation’s major shareholder updates its 13D with new derivative financing and confirms a sizable stake. Gulf Hungary Holding Korlatolt Felelossegu Tarsasag and its subsidiary QH Hungary Holdings Limited report beneficial ownership of 3,640,129 shares of Quaker Chemical common stock, representing about 21.0% of the 17,340,035 shares outstanding as of October 27, 2025. QH Hungary directly owns 3,635,112 shares, while Gulf Hungary directly holds 5,017 shares held in escrow to secure indemnification obligations under a share purchase agreement.

On November 25, 2025, QH Hungary amended and restated existing prepaid variable share forward arrangements with Citibank and Royal Bank of Canada and entered into new supplemental confirmations with both banks. It paid Citibank $3,246,816 and delivered 45,000 shares, and paid RBC $2,164,547 and delivered 30,000 shares in connection with the amended contracts, while receiving $1,699,801 from Citibank and $1,133,241 from RBC for new contracts. These forward deals cover specified maximum share amounts, use price thresholds of $139.28 and $153.21 per share to determine ultimate share or cash delivery, and have settlement dates scheduled between November 29, 2027 and January 3, 2028. After these transactions, the reporting persons’ aggregate beneficial ownership percentage in Quaker Chemical remains unchanged at approximately 21.0%.

Quaker Houghton (KWR) has a planned sale notice under Rule 144 for shares of its common stock, $1 par value. The seller intends to sell 13,900 shares through Citigroup Global Markets Inc. and 9,267 shares through RBC Capital Markets, LLC, with both trades listed for execution on the NYSE on approximately 11/25/2025. For context, the filing notes that 17,340,035 shares of this class were outstanding.

The securities to be sold trace back to a private acquisition on 08/01/2019, when 4,273,951 shares of common stock were acquired from Quaker Chemical Corporation in exchange for all of the equity of Global Houghton Ltd. The signer represents that they are not aware of any undisclosed material adverse information about Quaker Houghton’s current or prospective operations.

Quaker Chemical (KWR) reported higher quarterly sales but lower earnings. Q3 2025 net sales were $493.8 million, up from $462.3 million a year ago, driven by broad growth across Americas, EMEA and Asia/Pacific. Operating income was $46.6 million versus $51.7 million, and net income was $30.5 million with diluted EPS of $1.75, down from $1.81.

For the nine months, the company recorded a net loss of $23.2 million, primarily reflecting an $88.8 million non-cash goodwill impairment in EMEA recognized in Q2. Year-to-date restructuring and related charges were $31.1 million. Cash from operations was $89.9 million, while investing cash outflows of $193.0 million reflect acquisitions, notably Dipsol.

The April 2025 Dipsol acquisition totaled $185.6 million and contributed $20.6 million of sales in Q3 and $41.5 million year-to-date. To fund deals, debt increased: total debt was $875.2 million as of September 30, 2025, including $224.1 million drawn on the revolver. Quaker ended Q3 with $172.0 million in cash, declared a quarterly dividend of $0.508 per share, and continued share repurchases. Accumulated other comprehensive loss improved, aided by currency translation gains.

Quaker Chemical Corporation reported that it announced results of operations for the third quarter ended September 30, 2025. The company furnished a press release and related supplemental information to summarize its Q3 2025 performance and financial condition.

The materials are provided as Exhibits 99.1 (press release dated October 30, 2025) and 99.2 (supplemental information for the third quarter ended September 30, 2025). These exhibits offer the detailed financial and operating updates for the period.

Quaker Chemical (KWR) reported an insider equity award. The company’s SVP, CTO filed a Form 4 for the grant of 913 time‑based restricted stock units on 10/15/2025 under the Long‑Term Performance Incentive Plan.

The RSUs vest in three annual installments beginning on March 15, 2026. Each RSU represents a right to receive one share of KWR common stock, and dividend equivalent rights accrue when and as dividends are paid. Following the transaction, 913 derivative securities were beneficially owned, held directly.